Abstract
CP-31398 is a prototype small molecule that stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53. Here, we report that CP-31398 induces p53 reporter gene activity and p21 expression in all of 11 glioma cell lines harboring wild-type or mutant p53, but not in p53-null LN-308 cells. Upon prolonged exposure to CP-31398, all glioma cell lines undergo caspase-independent and bcl-xL-insensitive cell death with EC50 concentrations of 10–36 μ M. By comparing p53 wild-type U87MG and p53-null LN-308 cells expressing the temperature-sensitive p53V135A mutant, we delineate two pathways of CP-31398-induced cell death: an early, p53-dependent pathway that requires (new p53) protein synthesis and a late, p53-independent pathway characterized by aurintricarboxylic acid -sensitive calcium release and epiphenomenal free radical formation. Post-transcriptional repression of p53 synthesis by an intracellularly transcribed short interfering RNA confirmed the presence of these two pathways of cell death. These observations point out some of the liabilities of CP-31398 as a prototype p53-based therapeutic and define a rationale for further refinement of small molecules that specifically target the p53 pathway, but lack the p53-independent effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- ALLN:
-
N-acetyl-Leu-Leu-Nle-CHO
- AnxV-FITC:
-
annexinV-FITC
- ATA:
-
aurintricarboxylic acid
- CA-074ME:
-
L-3-trans-(prolylcarbamoyl)oxirane-2-carbonyl-L-isoleucyl-L-proline methyl ester
- CD95L:
-
CD95 ligand
- CHX:
-
cycloheximide
- DCFH-DA:
-
2′,7′-dichlorodihydrofluorescein diacetate
- DEVD-amc:
-
Asp-Glu-Val-Asp-7-amino-4-methylcoumarin
- DMSO:
-
dimethylsulfoxide
- ECL:
-
enhanced chemiluminescence
- HRP:
-
horseradish peroxidase
- NAC:
-
N-acetylcysteine
- PBN:
-
N-t-butyl-α-phenylnitrone
- PBS:
-
phosphate-buffered saline
- PCR:
-
polymerase chain reaction
- PI:
-
propidium iodide
- SEM:
-
standard error of the mean
- SFI:
-
specific fluorescence index
- siRNA:
-
short interfering RNA
- SSCP:
-
single-strand conformational polymorphism
- zFA-fmk:
-
N-tert-butoxy-carbonyl-Phe-Ala-fluoromethylketone
- zVAD-fmk:
-
N-tert-butoxy-carbonyl-Val-Ala-DL-Asp-fluoromethylketone
References
Brummelkamp TR, Bernards R and Agami R . (2002). Science, 296, 550–553.
Bullock AN . (2001). Nat. Rev. Cancer, 1, 68–76.
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G . (2002). Nat. Med., 8, 282–288.
Dringen R, Kussmaul L and Hamprecht B . (1998). Brain Res. Protoc., 2, 223–228.
Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F and Jacks T . (2002). Nature, 416, 560–564.
Foster BA, Coffey HA, Morin MJ and Rastinejad F . (1999). Science, 286, 2507–2510.
Glaser T, Wagenknecht B, Groscurth P, Krammer PH and Weller M . (1999). Oncogene, 18, 5044–5053.
Glaser T, Wagenknecht B and Weller M . (2001). Oncogene, 20, 4757–4767.
Haupt Y, Rowan S, Shaulian E, Kazaz A, Vousden K and Oren M . (1997). Leukemia, 11 (Suppl. 3), 337–339.
Haupt Y, Rowan S, Shaulian E, Vousden KH and Oren M . (1995). Genes Dev., 9, 2170–2183.
Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC and Van Meir EG . (1999). Brain Pathol., 9, 469–479.
Jiang ZY, Woollard AC and Wolff SP . (1991). Lipids, 26, 853–856.
Kaku S, Albor A and Kulesz-Martin M . (2001). Biochem. Biophys. Res. Commun., 280, 204–211.
Llanos S, Clark PA, Rowe J and Peters G . (2001). Nat. Cell. Biol., 3, 445–452.
Lotem J, Peled-Kamar M, Groner Y and Sachs L . (1996). Proc. Natl. Acad. Sci. USA, 93, 9166–9171.
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC . (1994). Oncogene, 9, 1799–1805.
Morgenstern JP and Land H . (1990). Nucleic Acids Res., 18, 1068.
Nakano K and Vousden KH . (2001). Mol. Cell, 7, 683–694.
Naumann U, Durka S and Weller M . (1998). Oncogene, 17, 1567–1575.
Naumann U, Kügler S, Wolburg H, Wick W, Rascher G, Schulz JB, Conseiller E, Bähr M and Weller M . (2001). Cancer Res., 61, 5833–5842.
Naumann U and Weller M . (1998). Int. J. Cancer, 77, 645–648.
Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T and Tanaka N . (2000). Science, 288, 1053–1058.
Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B . (1997). Nature, 389, 300–305.
Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG and Fersht AR . (2002). Oncogene, 21, 2119–2129.
Schmidt F, Rieger J, Wischhusen J, Naumann U and Weller M . (2001). Eur. J. Pharmacol., 412, 21–25.
Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J and el-Deiry WS . (2002). Cancer Biol. Ther., 1, 47–55.
Takuma K, Lee E, Kidawara M, Mori K, Kimura Y, Baba A and Matsuda T . (1999). Eur. J. Neurosci., 11, 4204–4212.
Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N and Cavenee WK . (1994). Cancer Res., 54, 649–652.
Wang W, Takimoto R, Rastinejad F and El-Deiry WS . (2003). Mol. Cell. Biol., 23, 2171–2181.
Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P and Ohgaki H . (1996). Brain Pathol., 6, 217–223, discussion 23–24.
Weller M, Marini AM and Paul SM . (1992). Brain. Res., 594, 160–164.
Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A and Dichgans J . (1998). Int. J. Cancer, 79, 640–644.
Wick W, Grimmel C, Wagenknecht B, Dichgans J and Weller M . (1999). J. Pharmacol. Exp. Ther., 289, 1306–1312.
Yu J, Wang Z, Kinzler KW, Vogelstein B and Zhang L . (2003). Proc. Natl. Acad. Sci. USA, 100, 1931–1936.
Acknowledgements
We wish to acknowledge Mrs. Marie-Anne Camus for excellent technical assistance. This work was made possible by an award from the Jaqueline Seroussi Memorial Foundation, Tel Aviv, Israel, to MW.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wischhusen, J., Naumann, U., Ohgaki, H. et al. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22, 8233–8245 (2003). https://doi.org/10.1038/sj.onc.1207198
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207198
Keywords
This article is cited by
-
Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression
Cell Death & Disease (2022)
-
Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide
Scientific Reports (2021)
-
Recent aspects of the effects of zinc on human health
Archives of Toxicology (2020)
-
The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy
Cell Death & Disease (2019)
-
Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine
EPMA Journal (2019)